DKN-01 Plus Bevacizumab and Chemotherapy Shows Tolerability, Activity in MSS CRC
DKN-01/bevacizumab/chemotherapy had a tolerable safety profile and showcased clinical activity in patients with microsatellite stable colorectal cancer.
Stay updated with breaking news from Meredith Pelster. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DKN-01/bevacizumab/chemotherapy had a tolerable safety profile and showcased clinical activity in patients with microsatellite stable colorectal cancer.
/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
Topics to be addressed at the annual conference, which will bring more than 1900 attendees to Kissimmee, Florida, include the Enhancing Oncology Model, efforts to regulate pharmacy benefit managers, and 340B reform.
Press release content from Business Wire. The AP news staff was not involved in its creation.